Tag: EGRX

Turn Tax Selling Stocks into Tax Selling Bounce Stocks

by Fred Fuld III

A tax selling stock is a stock that is currently selling for a low price but was trading at much higher levels earlier in the year.

What is Tax Harvesting?

As the year-end approaches, many investors use the strategy called tax harvesting , which is selling stocks the have tanked to offset any gains that may have been established sometime during the year.

With strong selling, the price of stocks that have had big drops tends to fall far more than what would normally take place during the rest of the year.

What are Tax-Selling Bounce Stocks?

So traders and investors are on the lookout for tax selling bounce stocks that are heavily hit, hoping for a little (or big) bounce in January, once the tax selling is over.

Here are some stocks that are down over 75% year-to-date and have market caps in excess of $75 million. They are all based in the United States and re generating positive earnings.

CompanySymbolMarket CapP/EPrice
reAlpha Tech Corp.AIRE146.29M428.753.43
Ebix Inc.EBIX139.05M28.044.5
Eagle Pharmaceuticals IncEGRX75.18M6.365.79
Origin Materials IncORGN99.19M1.960.69

reAlpha Tech Corp., a real estate technology company with a focus on short-term rentals, operates under two main segments: Platform Services and Investment Services.

Platform Services offer AI-powered products and services to real estate professionals, including data analytics, property management tools, and automated property valuations. Investment Services connect investors with fractional ownership opportunities in short-term rental properties.

The company has recently launched a new AI-powered rental pricing tool and expanded its portfolio to include Miami, Florida. With growing revenue and a focus on artificial intelligence, reAlpha Tech Corp. may be well-positioned to benefit from the booming short-term rental market.

Ebix Inc. is a leading international supplier of on-demand software and e-commerce services, primarily focusing on the insurance, financial, travel, cash remittance, and healthcare industries. The company operates globally, providing end-to-end solutions ranging from infrastructure exchanges and carrier systems to agency systems and risk compliance solutions.

Ebix boasts a comprehensive portfolio of services including software development, consultancy services, life insurance, risk management, health and employee benefits, CRM, and applications software for property and casualty insurance. Its expertise lies in developing and deploying insurance and reinsurance exchanges on an on-demand basis using software-as-a-service (SaaS) enterprise solutions. These solutions cover a wide range, encompassing customer relationship management, front-end and back-end systems, and outsourced administrative and risk compliance services.

Ebix leverages its expertise in consulting, systems design and integration, IT and business process outsourcing, applications software, and web and application hosting to cater to the individual needs of various organizations. This comprehensive approach positions Ebix as a leading player in the on-demand infrastructure exchange market for insurance, financial, and healthcare industries.

Eagle Pharmaceuticals, Inc. is a fully diversified pharmaceutical company dedicated to advancing safe and effective treatments for patients, healthcare providers, and the healthcare system as a whole. The company focuses its efforts on critical care and oncology, developing and commercializing injectable products in areas where there are unmet medical needs.

Eagle’s portfolio consists of four approved products:

  • Argatroban: An injectable anticoagulant used to treat and prevent blood clots in patients with heparin-induced thrombocytopenia (HIT).

Ryanodex: The only FDA-approved treatment for exertional heatstroke, a life-threatening condition caused by excessive exertion in hot environments.

Belrapzo: A monoclonal antibody approved for the treatment of adult patients with chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin’s lymphoma (NHL) who have failed or are intolerant to bendamustine and rituximab.

Bendeka: A liposomal encapsulation of bendamustine, a chemotherapy drug used to treat patients with CLL and indolent NHL.


Origin Materials, Inc. is a leading carbon-negative materials company on a mission to enable the world’s transition to sustainable materials. Their innovative platform transforms the carbon found in sustainable biomass, like wood residues and agricultural waste, into useful materials like bioplastics, biofuels, and carbon black. This process eliminates the need for fossil resources and captures carbon in the process, making Origin’s products truly carbon-negative.

Origin’s technology boasts several significant advantages. Their bio-based materials offer comparable performance to traditional petroleum-based materials while significantly reducing greenhouse gas emissions. This makes them attractive to companies seeking to reduce their environmental footprint and contribute to a more sustainable future. Additionally, Origin’s platform is highly scalable, allowing them to produce large quantities of their products to meet the growing demand for sustainable materials.

Currently, Origin is focused on two key markets:

  • Advanced bio-textiles: These bio-based alternatives to traditional textiles can be used in a variety of applications, including clothing, automotive interiors, and medical textiles.
  • Carbon black: This essential material is used in a variety of industrial applications, including tires, rubber products, and inks. Origin’s bio-based carbon black offers superior performance and environmental benefits over traditional carbon black derived from fossil fuels.

Origin may be well-positioned to capitalize on the growing demand for sustainable materials.

Hopefully, another investor’s loss can be your gain. However, keep in mind that these are all very low cap stocks and they may have been dropping substantially for a reason.

Disclosure: Author didn’t own any of the above at the time the article was written.

The Top Short Squeeze Stocks in Biotechnology

The biotechnology industry has some of the most volatile stocks, which may be one reason that stock traders like to trade them.

A trading strategy that has become popular is buying short squeeze stocks, the stocks that are heavily shorted but could move up quickly on any good news due to short sellers scrambling to buy in their positions.

When you short a stock, it means that you expect to make money from a drop in the price of a stock. Technically what happens is that you borrow shares of a stock, sell those shares, then buy back those shares at a hopefully lower price so that those shares can be returned. Of course, this all happens electronically, you don’t actually see all the borrowing and returning of shares; it just shows up on your computer screen as a negative number of shares.

Short sellers can make a lot of money, but sometimes when the stock moves against them, the stock starts to move up, and the short sellers jump in at once to buy shares to cover their position. This is called a short squeeze. When a short squeeze takes place, it can cause the stock to rise fast and hard. Any type of positive news can trigger the short squeeze.

So other traders take advantage of this situation buy looking for stocks to buy that may have a potential short squeeze. Here is what they look for:

  • Short Percentage of Float ~ The float is the number of freely tradable shares and the short percentage is the number of shares held short divided by the float. Amounts over 10% to 20% are considered high, and potential short squeeze plays.
  • Short Ratio / Days to Cover / Short Interest Ratio -This is probably the most important metric when looking for short squeeze trades, no matter what you call it. This is the number of days it would take the short sellers to cover their position based on the average daily volume of shares traded. This is a significant ratio as it shows how “stuck” the short sellers are when they want to buy in their shares without driving up the price too much. Unfortunately for the shortsellers, the longer the number of days to cover, the bigger and longer the squeeze.
  • Short Percentage Increase ~ This is the percentage increase in in the number of short sellers from the previous month.

Here are some stocks that are heavily shorted that may warrant a closer look. Remember that some stocks are heavily shorted for a reason.

Insys Therapeutics (INSY) has 68% of the float shorted, and a short interest ratio, also known as days to cover, of 14.5. This means that based on the current average daily volume, it would take almost 15 days for short sellers to cover their positions.

Egalet Corp (EGLT) has 64% of the float shorted, with a days to cover ratio of 9.5.

Heron Therapeutics (HRTX) has a short interest ratio of 12.8 and 55% of the float shorted.

Lannett Company (LCI) has 45% of the float shorted, with a short interest ratio of 10.1.

TherapeuticsMD (TXMD) has 39% of the float shorted, with a short interest ratio of 31.9.

Eagle Pharmaceuticals (EGRX) has 42.5%of the float shorted, with a short interest ratio of 11.3. This company also has a very low float and very low number of shares outstanding.

With any luck, you may be able to make a short term profit on short squeeze stocks.

Disclosure: Author didn’t own any of the above at the time the article was written.